The Prix Galien Award, which originated in France in 1970 to commemorate the father of medical science and modern pharmacology, honors excellence in biopharmaceutical research and development aimed at improving the human condition. It is considered the highest accolade in the biomedical industry and the industry's equivalent of the Nobel Prize.
Imbruvica is a prescription medicine approved by the Food and Drug Administration for use in individuals with chronic lymphocytic leukemia (CLL) who have received at least one prior treatment, those with CCL who carry a deletion in chromosome 17, patients who have been previously treated for mantle cell lymphoma (MCL) and people with Waldenstrom macroglobulinemia (WM), which is a type of non-Hodgkin's lymphoma. The drug interferes with the function of Bruton's tyrosine kinase (BTK) and blocks signals that would otherwise allow the growth of cancerous B cells.
Imbruvica was developed by Pharmacyclics, LLC, an AbbVie company, and Janssen Biotech, Inc.
"We are honored that Imbruvica, a first-in-class, oral therapy, has been recognized by the Prix Galien USA Committee for the role it continues to play in treating patients with certain blood cancers," Pharmacyclics President Erik von Borcke said. "Our goal is to continue developing clinically meaningful, scientifically sound therapies that offer health care professionals and their patients the opportunity at the best possible outcome, allowing them to resume as normal a life as possible."